

# Ian J Jacobs

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6277509/ian-j-jacobs-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185  
papers

13,829  
citations

58  
h-index

114  
g-index

192  
ext. papers

15,429  
ext. citations

7.3  
avg, IF

5.66  
L-index

#	Paper	IF	Citations
185	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. <i>Journal of Medical Genetics</i> , <b>2021</b> ,	5.8	5
184	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. <i>Trials</i> , <b>2021</b> , 22, 173	2.8	1
183	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , <b>2021</b> , 397, 2182-2193	4.0	68
182	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
181	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. <i>Trials</i> , <b>2021</b> , 22, 88	2.8	1
180	Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the Pro screen arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 316-322	4.9	3
179	Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	1
178	Improved early detection of ovarian cancer using longitudinal multimarker models. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 847-856	8.7	31
177	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
176	Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. <i>American Journal of Obstetrics and Gynecology</i> , <b>2020</b> , 222, 56.e1-56.e17	6.4	11
175	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. <i>Cancer Prevention Research</i> , <b>2019</b> , 12, 391-400	3.2	12
174	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 483-489	8.7	14
173	The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. <i>Scientific Reports</i> , <b>2019</b> , 9, 15787	4.9	5
172	Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. <i>Menopause</i> , <b>2019</b> , 26, 1100-1009	2.5	13
171	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4726-4733	12.9	26
170	Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. <i>BMJ, The</i> , <b>2018</b> , 362, k2644	5.9	26
169	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>F1000Research</i> , <b>2018</b> , 7, 1241	3.6	1

168	A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer. <i>Biomedical Signal Processing and Control</i> , <b>2018</b> , 46, 86-93	4.9	9
167	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. <i>Journal of Medical Genetics</i> , <b>2018</b> , 55, 546-554	5.8	30
166	Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 501-508	8.7	50
165	The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 1111-1117	8.7	6
164	Change-point of multiple biomarkers in women with ovarian cancer. <i>Biomedical Signal Processing and Control</i> , <b>2017</b> , 33, 169-177	4.9	11
163	Impact of a decision aid about stratified ovarian cancer risk-management on women's knowledge and intentions: a randomised online experimental survey study. <i>BMC Public Health</i> , <b>2017</b> , 17, 882	4.1	8
162	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1411-1420	2.2	105
161	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5912-5922	12.9	31
160	Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , <b>2017</b> , 7, e011822	3	6
159	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , <b>2017</b> , 17, 603	4.1	10
158	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 666-674	8.7	29
157	Novel risk models for early detection and screening of ovarian cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 785-797	3.3	10
156	Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 3811-3825	3.3	31
155	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , <b>2016</b> , 387, 945-956	40	563
154	Genetic screening for gynecological cancer: where are we heading?. <i>Future Oncology</i> , <b>2016</b> , 12, 207-20	3.6	10
153	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1734-1743	12.9	58
152	Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>PLoS ONE</i> , <b>2016</b> , 11, e0165539	3.7	6
151	Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). <i>Steroids</i> , <b>2016</b> , 110, 62-69	2.8	11

150	Protein Z: A putative novel biomarker for early detection of ovarian cancer. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2984-92	7.5	35
149	Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, 379	9.7	112
148	Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, 380	9.7	111
147	Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , <b>2015</b> , 15, 253	4.1	8
146	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2062-71	2.2	133
145	Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study. <i>Menopause</i> , <b>2015</b> , 22, 384-90	2.5	18
144	A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. <i>Journal of Medical Genetics</i> , <b>2015</b> , 52, 465-75	5.8	43
143	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2901-7	2.2	200
142	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	239
141	Multiprobabilistic prediction in early medical diagnoses. <i>Annals of Mathematics and Artificial Intelligence</i> , <b>2015</b> , 74, 203-222	0.8	9
140	Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. <i>BioMed Research International</i> , <b>2015</b> , 2015, 681416	3	18
139	Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. <i>International Journal of Gynecological Cancer</i> , <b>2015</b> , 25, 1519-25	3.5	9
138	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. <i>Genome Medicine</i> , <b>2015</b> , 7, 108	14.4	110
137	Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 622-31	12.9	124
136	Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. <i>Proteomics - Clinical Applications</i> , <b>2014</b> , 8, 982-93	3.1	34
135	Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. <i>Journal of Medical Genetics</i> , <b>2014</b> , 51, 108-13	5.8	47
134	Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , <b>2014</b> , 4, e004421	3	11
133	Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMJ Open</i> , <b>2014</b> , 4, e005400	3	6

132	Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 2180-88	7.5	45
131	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. <i>Genome Medicine</i> , <b>2014</b> , 6, 47	14.4	48
130	In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. <i>BMC Cell Biology</i> , <b>2013</b> , 14, 43		35
129	Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. <i>Journal of Proteome Research</i> , <b>2013</b> , 12, 1408-18	5.6	77
128	Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2013</b> , 42, 472-7	5.8	9
127	Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. <i>PLoS Medicine</i> , <b>2013</b> , 10, e1001551	11.6	100
126	Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 49-57	2.2	103
125	Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS Phase 2).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5507-5507	2.2	5
124	Withdrawal from familial ovarian cancer screening for surgery: findings from a psychological evaluation study (PsyFOCS). <i>Gynecologic Oncology</i> , <b>2012</b> , 124, 158-63	4.9	12
123	Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , <b>2012</b> , 286, 1555-62	2.5	28
122	Conformal predictors in early diagnostics of ovarian and breast cancers. <i>Progress in Artificial Intelligence</i> , <b>2012</b> , 1, 245-257	4	10
121	The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. <i>PLoS Genetics</i> , <b>2012</b> , 8, e1002517	6	88
120	Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 114-24	9.7	39
119	Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, 137-47	5.7	28
118	The UKCTOCS experience--reasons for hope?. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22 Suppl 1, S18-20	3.5	19
117	Multiprobabilistic Venn Predictors with Logistic Regression. <i>International Federation for Information Processing</i> , <b>2012</b> , 224-233		5
116	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. <i>Trials</i> , <b>2011</b> , 12, 61	2.8	32
115	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. <i>Journal of Clinical Epidemiology</i> , <b>2011</b> , 64, 525-30	5.7	27

114	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 38-48	21.7	138
113	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 2063-74	7.5	49
112	The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 299-302	3.2	13
111	Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. <i>Carcinogenesis</i> , <b>2011</b> , 32, 1540-46	4.6	33
110	Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 600-4	4	20
109	Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. <i>Clinical Chemistry</i> , <b>2010</b> , 56, 262-71	5.5	30
108	Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. <i>Neoplasia</i> , <b>2010</b> , 12, 317-25	6.4	66
107	Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. <i>Neoplasia</i> , <b>2010</b> , 12, 579-89	6.4	32
106	Development of a multimarker assay for early detection of ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2159-66	2.2	219
105	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. <i>Genome Research</i> , <b>2010</b> , 20, 440-6	9.7	638
104	A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. <i>Proteomics</i> , <b>2010</b> , 10, 3388-92	4.8	30
103	Clinical value of immunohistochemically detected lymphatic and vascular invasions in clinically staged endometrioid endometrial cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 1074-9	3.5	19
102	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 2297-304	5.6	37
101	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 1869-78	5.6	16
100	Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 2349-57	10.1	52
99	Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 1037-44	7.5	10
98	The clonal evolution of metastases from primary serous epithelial ovarian cancers. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 1579-86	7.5	53
97	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 2214-8	7.5	50



96	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , <b>2009</b> , 41, 996-1000	36.3	240
95	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 327-40	21.7	615
94	Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2009</b> , 21, 31-8	2.4	20
93	An epigenetic signature in peripheral blood predicts active ovarian cancer. <i>PLoS ONE</i> , <b>2009</b> , 4, e8274	3.7	245
92	Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5840-8	12.9	33
91	The effects of common genetic variants in oncogenes on ovarian cancer survival. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5833-9	12.9	30
90	BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3761-7	12.9	77
89	Recruitment to multicentre trials—lessons from UKCTOCS: descriptive study. <i>BMJ, The</i> , <b>2008</b> , 337, a20795.9	5.9	105
88	Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. <i>PLoS ONE</i> , <b>2008</b> , 3, e2656	3.7	116
87	Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish MALOVA ovarian cancer study. <i>Pathology</i> , <b>2008</b> , 40, 487-92	1.6	18
86	HOXA11 DNA methylation—a novel prognostic biomarker in ovarian cancer. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 725-9	7.5	86
85	Clinical value of immunohistochemically detected lymphovascular space invasion in early stage cervical carcinoma. <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 2581-8	3.1	27
84	Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. <i>Apmis</i> , <b>2008</b> , 116, 400-9	3.4	16
83	Distribution of microsatellite instability in Danish ovarian tumor patients and the prognostic value in ovarian cancer patients. <i>Oncology Research</i> , <b>2008</b> , 17, 43-9	4.8	4
82	Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. <i>PLoS ONE</i> , <b>2007</b> , 2, e268	3.7	47
81	Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. <i>Human Mutation</i> , <b>2007</b> , 28, 1207-15	4.7	67
80	Screening for the BRCA1-ins6kbEx13 mutation: potential for misdiagnosis. Mutation in brief #964. Online. <i>Human Mutation</i> , <b>2007</b> , 28, 525-6	4.7	8
79	Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology. <i>Proteomics</i> , <b>2007</b> , 7 Suppl 1, 77-89	4.8	49

78	Epigenetic stem cell signature in cancer. <i>Nature Genetics</i> , <b>2007</b> , 39, 157-8	36.3	909
77	CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. <i>Gynecologic Oncology</i> , <b>2007</b> , 104, 508-15	4.9	90
76	Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study. <i>Gynecologic Oncology</i> , <b>2007</b> , 106, 318-24	4.9	18
75	Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2007</b> , 107, 526-31	4.9	80
74	Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 645-56	5.5	121
73	Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. <i>Cancer Research</i> , <b>2007</b> , 67, 3027-35	10.1	75
72	Decline in use of hormone therapy among postmenopausal women in the United Kingdom. <i>Menopause</i> , <b>2007</b> , 14, 462-7	2.5	30
71	Familial ovarian cancer screening. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2006</b> , 20, 321-38	4.6	16
70	Common variants in RB1 gene and risk of invasive ovarian cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 10220-6	10.1	34
69	Screening for ovarian cancer. <i>Clinical Obstetrics and Gynecology</i> , <b>2006</b> , 49, 433-47	1.7	65
68	Low frequency of BRAF and CDKN2A mutations in endometrial cancer. <i>International Journal of Cancer</i> , <b>2005</b> , 115, 930-4	7.5	41
67	Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2813-21	2.2	286
66	Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7919-26	2.2	190
65	Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4059-66	2.2	140
64	Significance of PTEN alterations in endometrial carcinoma: A population-based study of mutations, promoter methylation and PTEN protein expression <b>2004</b> , 25, 1615		4
63	Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. <i>Cancer Research</i> , <b>2004</b> , 64, 5882-90	10.1	796
62	A molecular genetic and statistical approach for the diagnosis of dual-site cancers. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1441-6	9.7	39
61	A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. <i>Laboratory Investigation</i> , <b>2004</b> , 84, 923-31	5.9	30



60	Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study. <i>Cancer</i> , <b>2004</b> , 100, 2387-95	6.4	8
59	Progress and challenges in screening for early detection of ovarian cancer. <i>Molecular and Cellular Proteomics</i> , <b>2004</b> , 3, 355-66	7.6	316
58	High-risk premenopausal women's experiences of undergoing prophylactic oophorectomy: a descriptive study. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2004</b> , 8, 148-56		23
57	Screening and Diagnosis of Ovarian Cancer in the General Population <b>2004</b> , 355-368		2
56	Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 206s-210s	2.2	177
55	Characterization of adnexal mass lesions on MR imaging. <i>American Journal of Roentgenology</i> , <b>2003</b> , 180, 1297-304	5.4	163
54	Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. <i>Gynecologic Oncology</i> , <b>2003</b> , 91, 218-25	4.9	15
53	MSI-low, a real phenomenon which varies in frequency among cancer types. <i>Journal of Pathology</i> , <b>2003</b> , 201, 389-94	9.4	44
52	Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. <i>Journal of Pathology</i> , <b>2003</b> , 201, 544-54	9.4	112
51	CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer <b>2003</b> , 193-200		1
50	Screening for familial ovarian cancer <b>2002</b> , 220-234		3
49	Screening for ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2002</b> , 16, 469-82	4.6	37
48	Molecular evidence of a common clonal origin and subsequent divergent clonal evolution in vulval intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node metastases. <i>International Journal of Cancer</i> , <b>2002</b> , 99, 549-54	7.5	38
47	MR imaging of carcinoma of the vulva. <i>American Journal of Roentgenology</i> , <b>2002</b> , 178, 373-7	5.4	84
46	Ovarian cancer screening. <i>British Journal of Hospital Medicine</i> , <b>2002</b> , 63, 210-3		8
45	Management of familial ovarian cancer <b>2002</b> , 275-285		1
44	Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 138-43	12.9	35
43	Ascites and a raised serum Ca 125--confusing combination. <i>Journal of the Royal Society of Medicine</i> , <b>2001</b> , 94, 581-2	2.3	16

42	PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. <i>International Journal of Cancer</i> , <b>2001</b> , 91, 22-6	7.5	235
41	High frequency of loss of heterozygosity in vulval intraepithelial neoplasia (VIN) is associated with invasive vulval squamous cell carcinoma (VSCC). <i>International Journal of Cancer</i> , <b>2001</b> , 94, 896-900	7.5	22
40	Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. <i>Laboratory Investigation</i> , <b>2001</b> , 81, 1363-70	5.9	25
39	Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Change-point and Mixture Models of Longitudinal Markers. <i>Journal of the American Statistical Association</i> , <b>2001</b> , 96, 429-439 <sup>2,8</sup>	3.8	110
38	Survival analysis in familial ovarian cancer, a case control study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2001</b> , 98, 219-23	2.4	18
37	Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. <i>Lancet, The</i> , <b>2001</b> , 357, 15-20	4.0	153
36	Ovarian cancer screening in the general population. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2001</b> , 13, 61-4	2.4	34
35	Recent developments in ovarian cancer screening. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2000</b> , 12, 39-42	2.4	81
34	Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. <i>International Journal of Cancer</i> , <b>2000</b> , 89, 519-523	7.5	21
33	Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2000</b> , 107, 1069-74	3.7	29
32	Patterns in the incidence of age-related ovarian cancer in South East England 1967-1996. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2000</b> , 107, 1094-6	3.7	10
31	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2000</b> , 107, 165-9	3.7	48
30	Ovarian cancer screening in the general population. <i>Ultrasound in Obstetrics and Gynecology</i> , <b>2000</b> , 15, 350-3	5.8	21
29	Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. <i>Gynecologic Oncology</i> , <b>2000</b> , 76, 45-50	4.9	162
28	Registration of ovarian cancer in England and Wales. <i>British Journal of Cancer</i> , <b>2000</b> , 83, 279-279	8.7	78
27	Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. <i>Cancer</i> , <b>1999</b> , 85, 2068-2072	6.4	16
26	OVX1 Radioimmunoassay Results Are Dependent on the Method of Sample Collection and Storage. <i>Clinical Chemistry</i> , <b>1999</b> , 45, 692-694	5.5	14
25	Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. <i>Radiology</i> , <b>1999</b> , 212, 395-9	20.5	106

24	Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. <i>Gynecologic Oncology</i> , <b>1999</b> , 73, 56-61	4.9	64
23	Increased mortality in postmenopausal women with serum CA125 elevation. <i>Gynecologic Oncology</i> , <b>1999</b> , 73, 242-6	4.9	5
22	Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. <i>Cancer</i> , <b>1999</b> , 85, 2068-72	6.4	9
21	Screening for ovarian cancer. <i>Lancet, The</i> , <b>1999</b> , 354, 510	4.0	
20	Screening for ovarian cancer: a pilot randomised controlled trial. <i>Lancet, The</i> , <b>1999</b> , 353, 1207-10	4.0	447
19	No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis. <i>Gynecologic Oncology</i> , <b>1998</b> , 68, 14-7	4.9	17
18	p53 codon 72 polymorphism and risk of cervical cancer in UK. <i>Lancet, The</i> , <b>1998</b> , 352, 871-2	4.0	173
17	Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. <i>BMJ: British Medical Journal</i> , <b>1996</b> , 313, 1355-8		14.0
16	Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. <i>Gynecologic Oncology</i> , <b>1995</b> , 59, 111-6	4.9	91
15	Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. <i>Cancer</i> , <b>1995</b> , 76, 1615-20	6.4	16
14	Molecular approaches to prevention and detection of epithelial ovarian cancer. <i>Journal of Cellular Biochemistry</i> , <b>1995</b> , 23, 219-22	4.7	17
13	Non-surgical aspects of ovarian cancer. <i>Lancet, The</i> , <b>1994</b> , 343, 335-340	4.0	16
12	Cell growth regulation in epithelial ovarian cancer. <i>Cancer</i> , <b>1993</b> , 71, 1597-601	6.4	66
11	The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1993</b> , 100, 927-31	3.7	110
10	Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1993</b> , 100, 1120-4	3.7	36
9	Prevention of ovarian cancer: a survey of the practice of prophylactic oophorectomy by fellows and members of the Royal College of Obstetricians and Gynaecologists. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1989</b> , 96, 510-5	3.7	52
8	The CA 125 tumour-associated antigen: a review of the literature. <i>Human Reproduction</i> , <b>1989</b> , 4, 1-12	5.7	551
7	SCREENING FOR EARLY OVARIAN CANCER. <i>Lancet, The</i> , <b>1988</b> , 332, 171-172	4.0	4

6	Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>1988</b> , 29, 73-85	2.4	64
5	Multimodal approach to screening for ovarian cancer. <i>Lancet, The</i> , <b>1988</b> , 1, 268-71	4.0	178
4	The value of CA 125 serum assay in the management of ovarian cancer. Commentary. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1987</b> , 94, 819-21	3.7	2
3	Ovarian Cancer Screening47-68		0
2	Screening for Ovarian Cancer144-150		
1	A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors		2